Knowledge HQ

This poster outlines a semi-automated GMP platform using artificial antigen presenting cells (aAPCs) to generate AML-specific CD8+ T cells. Following magnetic enrichment, the antigen-specific T cells were successfully expanded to clinically relevant numbers using G-REX expansion over a 14-day period.

The Cell Trajectory Modulation (CTM) assay provides rapid, label-free profiling of CAR T cell biophysical features like size and deformability. The study compares CAR T cells manufactured in G-Rex gas-permeable plates versus perfusion bioreactors, showing that biophysical signatures correlate with potency and phenotype.

This study demonstrates that NK cells engineered with mRNA to express an EphA2-targeted CAR exhibit enhanced cytotoxicity against pediatric sarcomas. The protocol involved expanding human primary NK cells in G-Rex 24 multi-well cell culture plates using supplemented NK MACS media and activation beads or feeder cells.

This study investigates the efficacy of Delta One T (DOT) cells against colorectal cancer. It identifies NKG2D ligand upregulation and simultaneous TIGIT/PD1 blockade as strategies to enhance cytotoxicity. The expansion protocol for producing clinical-grade DOT cells utilized the G-REX platform with OpTmizer-CTS medium.

This study develops affinity-tuned mesothelin (MSLN) CAR T cells to improve specificity and safety. Low-affinity variants showed effective tumor control with reduced off-tumor toxicity in mice. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process.

This study identifies an HLA-A*11:01-restricted TCR targeting KRAS G12V from a pancreatic cancer patient. T cells engineered with this TCR were expanded in G-Rex 24-well plates and showed specific recognition of tumor organoids, enhanced by IFN-gamma priming.

This study compares conventional and G-Rex systems for expanding BKPyV-specific T cells. G-Rex cultures resulted in higher total cell counts but increased PD-1 expression. The study highlights the need for optimization in adoptive T-cell therapy protocols for BKPyV.

This paper reports on BMS-986408, a dual DGK inhibitor that enhances PD-1 and CAR-T therapies. It improves T-cell signaling and effector function. CAR T cells were expanded in G-Rex 6M well plates during the manufacturing process for experimental assays.

This study demonstrates a process to manufacture Tumor-Associated Antigen-Specific T Cells (TAAT) by priming naïve T cells with MoDC directly in G-Rex devices. This closed-system approach eliminates the need for MoDC harvest and restimulation, yielding clinical doses from small blood volumes.

This abstract describes a streamlined protocol for manufacturing Monocyte-Derived Dendritic Cells (MoDC) using G-Rex devices. The method reduces cell loss associated with harvesting adherent cells and allows for the subsequent production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the same vessel.

This study presents MARC, a modular CAR design that mimics native receptors to prevent tonic signaling and exhaustion. Primary T cells were transduced and expanded in 24-well G-Rex plates, demonstrating improved persistence and efficacy in leukemia models compared to traditional CARs.

This paper introduces Cas9-CLIPT, a method for efficient non-viral CRISPR-Cas9 knock-in of large transgenes (like CARs) into T cells. G-Rex 6M well plates were used for the expansion of CAR T cells during the manufacturing process, supporting clinical scalability.